FinnCap Reiterates “Corporate” Rating for Akers Biosciences, Inc. (AKR)
Akers Biosciences, Inc. (LON:AKR)‘s stock had its “corporate” rating reiterated by investment analysts at FinnCap in a note issued to investors on Monday.
Shares of Akers Biosciences (LON:AKR) opened at 240.00 on Monday. The company’s market capitalization is GBX 13.08 million. The company’s 50-day moving average is GBX 236.82 and its 200-day moving average is GBX 202.24. Akers Biosciences has a one year low of GBX 78.75 and a one year high of GBX 255.00.
About Akers Biosciences
Akers Biosciences, Inc develops, manufactures and supplies point-of-care screening and testing products designed to bring health-related information to the patient or clinician. The Company’s product offerings and pipeline products focus on delivering diagnostic assistance in a range of healthcare fields/specialties, including cardiology/emergency medicine, metabolism/nutrition, diabetes, respiratory diseases and infectious diseases detection, as well as for on and off-the-job alcohol safety initiatives.
Receive News & Stock Ratings for Akers Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akers Biosciences Inc. and related stocks with our FREE daily email newsletter.